Company news
Todos Medical Ltd. (OTC:TOMDF) news
Todos Medical Ltd. news releases on 6ix. Latest, Dec 22, 2023: Todos Medical Announces Insolvency Proceedings in Israel
Press releases & updates
Todos Medical Announces Insolvency Proceedings in Israel
December 21, 2023
Todos Medical Provides Corporate Update: Retooling to Focus on Long COVID Epidemic
September 25, 2023
Todos Announces Notice of Allowance From USPTO for Patent Application Covering Use of Compositions In Tollovid™ and Tollovir™ Ingredients
August 29, 2023
Todos Medical Enters Into Letter of Intent for Provista Diagnostics to License PCR-based Sepsis Diagnostic Test AcuSept LDT Rights From Acumen Diagnostics
March 27, 2023
Todos Medical Begins Trading on the OTC Pink Marketplace
March 26, 2023
Todos Medical Supports Long COVID Awareness Day
March 14, 2023
Todos Medical Enters Into Moratorium on Conversions Agreement With Convertible Note Holders
March 12, 2023
Todos Medical Provides Corporate Update
February 23, 2023
Todos Medical Initiates Validation Plan for PCR-based Avian Influenza A (H5N1, Bird Flu) Test at CLIA/CAP Testing Lab Provista Diagnostics
February 14, 2023
Todos Medical to Present at the RHK 2022 Disruptive Growth Conference
December 6, 2022
Todos Medical’s 3CL Pharma Awarded Oral and Poster Presentations at World Antiviral Congress 2022
November 29, 2022
Todos Medical to Attend World Antiviral Congress
November 22, 2022
Todos Medical Enters Into Exclusive Worldwide Automated Retail Supply Agreement With Smart Automated Retail Network
November 16, 2022
Todos Medical Announces Third Quarter 2022 Financial Results
November 15, 2022
Todos Medical to Host Third Quarter 2022 Earnings and Business Update Conference Call on November 15, 2022
November 14, 2022
Todos Medical Terminates Tollovid™ Products License & Distribution Agreement with T-Cell Protect Hellas S.A.
November 10, 2022
Todos Medical Announces BioFuture™ NYC 2022 Presentation
November 4, 2022
Todos Medical CLIA/CAP Lab Provista Submits Emergency Use Authorization Application for MonkeyPox PCR Test to US FDA
October 14, 2022
Presenting on the Emerging Growth Conference on October 12 Register Now
October 11, 2022
Todos Medical Announces Successful Pilot Launch of Suite of PCR Testing Services by CLIA/CAP Lab Provista Diagnostics
October 6, 2022
Todos Medical Receives Two Notices of Allowance from USPTO for AI-Based TBIA Pan-Cancer Blood Diagnostics Platform
September 30, 2022
Todos Medical Announces USPTO Trademark Notice of Allowance for 3CL Protease Biomarker Diagnostics TolloTest™
September 27, 2022
Todos Medical Enters Into $50M Contract to Supply Tollovid™ and CBD Products to Retail Distributor Company Nerd Hemp
September 22, 2022
Todos Medical Announces NFL Hall of Famer Michael Irvin as Tollovid™ Sports Ambassador for #TolloUp Campaign
September 16, 2022
Todos Medical Announces Preprint of Long COVID Case Study Participant with Confirmed Microclot and Hyperactivated Platelets who Benefitted from Tollovid
September 15, 2022
Todos Medical Initiates Validation Plan for PCR-based Polio Testing at CLIA/CAP Laboratory Provista Diagnostics
September 14, 2022
Todos Medical & The Alchemist’s Kitchen to Host “Long COVID: An Integrated Approach” Event Benefitting Survivor Corps
September 13, 2022
Todos Medical’s 3CL Protease Inhibitor Supplement Tollovid™ Featured in Wellness Magazine
September 13, 2022
Todos Medical Partner NLC Pharma Assigns IP for Tollovir™, Tollovid™, and TolloTest™ into JV 3CL Pharma
September 12, 2022
Todos Medical CEO Discusses Long COVID Economic Impact with Moneta Advisory Managing Partner Marc LoPresti
September 9, 2022
Todos Medical Announce Kingcarlx as Brand Ambassador for the Tollovid #TolloUp Lifestyle Campaign
September 2, 2022
Todos Medical Establishes Botanical Supplement Manufacturing Capabilities to Support Tollovid Global Expansion and Initiates CBD-A Production
August 31, 2022
Todos Medical Expands COVID Onsite School Sample Collection to Include MonkeyPox Testing
August 29, 2022
Todos Medical Announces Saliva-Only MonkeyPox Testing at CLIA/CAP Clinical Lab Provista Diagnostics
August 26, 2022
Todos Medical Enrolls Female Long COVID Patient Unable to Secure Testing While Symptomatic for MonkeyPox into Provista Diagnostics Case Study Series
August 25, 2022
Todos Medical Initiates MonkeyPox Diagnostic Case Studies After Being Approached by 4 Patients, Including 3 Women
August 23, 2022
Todos Medical Reports Second Quarter 2022 Financial Results and Business Update Conference Call on Tuesday, August 23 at 8:30am ET
August 21, 2022
Todos Medical Announces Commercialization of Lesion and Saliva-Based MonkeyPox PCR Testing
August 22, 2022
Todos Medical Announces Preprint of Data from First 100 Participants in IRB-waived Market Research Study of Supplementation with Tollovid in Long COVID
August 19, 2022
Todos Medical Reports Pre-Print of Publication Detailing Tollovid Supplementation Following COVID-19 mRNA Vaccination in Long COVID
August 15, 2022
Todos Medical Completes Trial Design for Tollovid™ Long COVID Clinical Study in Adults
August 11, 2022
Todos Medical Announces PCR Validation of Wound and Respiratory Pathogen Panels at CLIA/CAP Lab Provista Diagnostics
August 10, 2022
Todos Medical Announces First Two Contracts for PCR-based MonkeyPox Testing at CLIA/CAP Clinical Testing Laboratory Provista Diagnostics
August 8, 2022
Todos Medical Announces First Long COVID Clinic Laboratory Services Agreement for Long COVID Panel Biomarker Partnership with Amerimmune Diagnostics
August 5, 2022
Todos Medical Initiates Validation Plan for PCR-based MonkeyPox Test at CLIA/CAP Clinical Testing Laboratory Provista Diagnostics
August 3, 2022
Todos Medical Announces Preprint of Acute COVID-19 Paxlovid Rebound Rescued by Tollovid
August 1, 2022
Todos Medical Partners with Amerimmune Diagnostics on Long COVID Biomarker Panel
July 28, 2022
Todos Medical Announces Preprint of Chronic Long COVID Case Study #8 of Paxlovid® Treatment Followed by Tollovid™ Dietary Supplementation
July 22, 2022
Todos Medical Reports Case Study #7 in Acute and Long COVID
July 12, 2022
Todos Medical Announces Positive Biomarker Data from Phase 2 Trial of Tollovir in Hospitalized COVID-19 Patients
June 30, 2022